2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
54
Lymphoma, Mantle-Cell
31
Lymphoma, Large B-Cell, Diffuse
17
Lymphoma, Non-Hodgkin
14
Lymphoma
11
Leukemia, B-Cell
7
Lymphoma, Follicular
5
Lymphoma, B-Cell, Marginal Zone
5
Lymphoma, B-Cell
5
Leukemia
5
Waldenstrom Macroglobulinemia
4
Multiple Myeloma
3
Recurrence
2
Pancreatic Neoplasms
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Leukemia, Prolymphocytic
2
Hematologic Neoplasms
2
Cardiovascular Diseases
2
Squamous Cell Carcinoma of Head and Neck
1
Pyloric Stenosis, Hypertrophic
1
Part1: Advanced B-cell Malignancies
1
Ovarian Neoplasms
1
Neuritis
1
Neoplasms
1
Neoplasm, Residual
1
Leukemia, Hairy Cell
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Interventions
Brentuximab Vedotin
21
Cyclophosphamide
20
fludarabine
16
Rituximab
13
Lenalidomide
13
Dexamethasone
12
fludarabine phosphate
10
Melphalan
10
Busulfan
10
Mycophenolic Acid
9
pirtobrutinib
7
dacetuzumab
7
Whole-Body Irradiation
7
Tacrolimus
7
Bortezomib
7
Doxorubicin
6
Azacitidine
6
ruxolitinib
5
Vincristine
5
Prednisone
5
Imatinib Mesylate
5
Bone Marrow Transplantation
5
ponatinib
4
pomalidomide
4
Mesna
4
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Blood Specimen Collection
4
Bendamustine Hydrochloride
4
venetoclax
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
acalabrutinib
×
Clear all
NCT04662255
2026-05-15
BRUIN-MCL-321
Eli Lilly and Company
Phase 3
Active not recruiting
500 enrolled